Pay in 4 interest-free payments of $6.70 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
REDEFINE Clinical Trial Program Overview The REDEFINE program is a comprehensive Phase 3 clinical trial initiative evaluating CagriSema across diverse populations and settings: Expected Completion: The REDEFINE program is anticipated to complete enrollment and report results between 2024-2026, providing comprehensive data to support regulatory submissions worldwide
It also yields many other health benefits, including increased energy, stronger immunity, and detoxification
doi: 10.1038/s41598-019-46333-2 206 HanMLeeDLeeSHKimTH
doi: 10.1056/NEJMoa1012985 172
Data are representative of three mice per group and at least three independent experiments
US$ 28.23
US$ 25.50
US$ 26.93
